Ajanta Pharma Q4 Revenue Climbs to Rs 1,422 Cr, Profit Up 18%
New Delhi: Ajanta Pharma Ltd on Tuesday reported a 18.4 per cent rise in consolidated net profit at Rs 266.7 crore in the fourth quarter ended March 31, on the back of strong US generics revenue growth.
The company had posted a consolidated net profit of ₹225.26 crore in the corresponding period previous fiscal, Ajanta Pharma Ltd said in a regulatory filing.
Consolidated revenue from operations in the fourth quarter stood at ₹1,421.64 crore as against ₹1,170.41 crore in the year-ago period, it added.
During the quarter branded generics in the markets of India, Asia and Africa clocked a combined revenue of ₹859 crore as compared to ₹805 crore in the year-ago period, up 7 per cent.
US generic revenue was at ₹505 crore as compared to ₹325 crore in the same period a year ago, up 56 per cent, the company said.
Total expenses in the fourth quarter were higher at ₹1,135.96 crore as compared to ₹919.11 crore in the same period a year ago, the company said.
For FY26, consolidated net profit was at ₹1,056 crore as compared to ₹920.39 crore in FY25.
Consolidated revenue from operations in FY26 stood at ₹5,452.86 crore as compared to ₹4,648.1 crore in FY25, the company said.
